Insulet (NASDAQ:PODD) Director Buys $400,392.90 in Stock

Insulet Corporation (NASDAQ:PODD) Director Timothy Stonesifer purchased 2,790 shares of the stock in a transaction that occurred on Wednesday, June 3rd. The stock was acquired at an average cost of $143.51 per share, with a total value of $400,392.90. Following the acquisition, the director owned 9,041 shares in the company, valued at $1,297,473.91. The trade was a 44.63% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website.

Insulet Stock Up 4.7%

Shares of NASDAQ:PODD opened at $153.22 on Friday. The company has a current ratio of 2.49, a quick ratio of 1.81 and a debt-to-equity ratio of 0.71. Insulet Corporation has a 12 month low of $140.63 and a 12 month high of $354.88. The company has a 50-day moving average price of $175.73 and a 200 day moving average price of $238.90. The company has a market cap of $10.61 billion, a price-to-earnings ratio of 35.63, a PEG ratio of 1.21 and a beta of 1.13.

Insulet (NASDAQ:PODD) last announced its quarterly earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 EPS for the quarter, beating analysts’ consensus estimates of $1.19 by $0.23. Insulet had a net margin of 10.44% and a return on equity of 26.87%. The firm had revenue of $761.70 million during the quarter, compared to the consensus estimate of $729.89 million. During the same quarter last year, the firm earned $1.02 EPS. The firm’s revenue for the quarter was up 33.9% compared to the same quarter last year. Insulet has set its FY 2026 guidance at 6.210- EPS. As a group, equities research analysts predict that Insulet Corporation will post 6.46 earnings per share for the current year.

Institutional Trading of Insulet

Several institutional investors and hedge funds have recently modified their holdings of PODD. NewEdge Advisors LLC raised its stake in shares of Insulet by 44.8% during the first quarter. NewEdge Advisors LLC now owns 207 shares of the medical instruments supplier’s stock valued at $54,000 after acquiring an additional 64 shares in the last quarter. Cresset Asset Management LLC raised its stake in shares of Insulet by 7.3% during the second quarter. Cresset Asset Management LLC now owns 2,587 shares of the medical instruments supplier’s stock valued at $813,000 after acquiring an additional 177 shares in the last quarter. Cerity Partners LLC raised its stake in shares of Insulet by 68.7% during the second quarter. Cerity Partners LLC now owns 17,262 shares of the medical instruments supplier’s stock valued at $5,423,000 after acquiring an additional 7,030 shares in the last quarter. Sei Investments Co. raised its stake in shares of Insulet by 27.4% during the second quarter. Sei Investments Co. now owns 137,643 shares of the medical instruments supplier’s stock valued at $43,245,000 after acquiring an additional 29,584 shares in the last quarter. Finally, Treasurer of the State of North Carolina raised its stake in shares of Insulet by 2.5% during the second quarter. Treasurer of the State of North Carolina now owns 32,752 shares of the medical instruments supplier’s stock valued at $10,290,000 after acquiring an additional 791 shares in the last quarter.

Wall Street Analyst Weigh In

Several brokerages have issued reports on PODD. Jefferies Financial Group decreased their price objective on shares of Insulet from $400.00 to $360.00 in a research note on Thursday, May 7th. William Blair began coverage on shares of Insulet in a research note on Wednesday, May 20th. They issued an “outperform” rating for the company. Raymond James Financial decreased their price objective on shares of Insulet from $355.00 to $263.00 in a research note on Thursday, May 7th. Rothschild & Co Redburn reissued a “neutral” rating and issued a $220.00 price objective (down from $380.00) on shares of Insulet in a research note on Friday, April 24th. Finally, TD Cowen decreased their price objective on shares of Insulet from $379.00 to $294.00 and set a “hold” rating for the company in a research note on Monday, June 1st. Twenty-one research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Insulet has an average rating of “Moderate Buy” and a consensus target price of $252.04.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.